Substance / Medication

Hemin

Overview

Active Ingredient
hemin
RxNorm CUI
5175

Indications

PANHEMATIN is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate. Limitations of Use • 2.1 [See Dosage and Administration ()] Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days). • Attacks of porphyria may progress to a point whe

Labeler: Recordati Rare Diseases, Inc.Updated: 2025-09-18T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

PANHEMATIN is contraindicated in patients with known hypersensitivity to this drug.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis.
Bharucha A E, Daley S L, Low P A et al. · Neurogastroenterol Motil · 2016
PMID: 27283929RCTFull text (PMC)
Hemin Preconditioning Upregulates Heme Oxygenase-1 in Deceased Donor Renal Transplant Recipients: A Randomized, Controlled, Phase IIB Trial.
Thomas Rachel A B, Czopek Alicja, Bellamy Christopher O C et al. · Transplantation · 2016
PMID: 26680374Trial
Hemin controls T cell polarization in sickle cell alloimmunization.
Zhong Hui, Bao Weili, Friedman David et al. · J Immunol · 2014
PMID: 24879794TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Hemin (substance)
SNOMED CT
27345002
UMLS CUI
C0018988
RxNorm CUI
5175
Labeler
Recordati Rare Diseases, Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.